Addex ceo steps down
Replacement being sought for Swiss allosteric modulators developer
André Mueller, chairman of Addex, will act as executive chairman and lead an operational subcommittee of directors to manage the transition until a new ceo is appointed.
Under Mutel's leadership, Addex says it has become a world leader in the field of allosteric modulator drug discovery and has formed significant drug development partnerships with leading pharmaceutical companies.
The board of directors has invited Mutel to consider a possible future advisory role at Addex.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Masters of synthesis
Medicinal chemists take an initial lead compound and through systematic design work improve its potency, efficacy, and properties such as solubility and metabolism. The aim is to create a molecule that is effective, has few side-effects and can be scaled up, initially for clinical trials and subsequently for commercial manufacturing.
